Cargando…

Long-Term Treatment of Metastatic Colorectal Cancer with Panitumumab

Colorectal cancer is one of the leading causes of cancer-related deaths worldwide. More than 30% patients present with metastases at diagnoses and will require systemic chemotherapy. In recent years many anti-EGFR targets have been developed. Among them, panitumumab, a fully human IgG2 monoclonal an...

Descripción completa

Detalles Bibliográficos
Autores principales:	López-Gómez, Miriam, Merino, María, Casado, Enrique
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Libertas Academica 2012
Materias:	Expert Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3296490/ https://www.ncbi.nlm.nih.gov/pubmed/22408376 http://dx.doi.org/10.4137/CMO.S5055

Ejemplares similares

Treatment of metastatic colorectal cancer: focus on panitumumab
por: Tay, Rebecca Y, et al.
Publicado: (2015)

Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer
por: Berardi, Rossana, et al.
Publicado: (2010)

Patient considerations in metastatic colorectal cancer – role of panitumumab
por: Rogers, Jane E
Publicado: (2017)

Panitumumab in Metastatic Colorectal Cancer: The Importance of Tumour RAS Status
por: Peeters, Marc, et al.
Publicado: (2015)

Management of skin toxicities during panitumumab treatment in metastatic colorectal cancer
por: Bouché, Olivier, et al.
Publicado: (2019)

Cicatricial ectropion and madarosis associated with panitumumab treatment of metastatic colorectal cancer
por: Jin, Haoxing D., et al.
Publicado: (2020)

Panitumumab: the evidence of its therapeutic potential in metastatic colorectal cancer care
por: Martinelli, Erika, et al.
Publicado: (2007)

Genetic and immune factors underlying the efficacy of cetuximab and panitumumab in the treatment of patients with metastatic colorectal cancer
por: Krawczyk, Paweł Adam, et al.
Publicado: (2013)

Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer
por: Patel, Shiven B, et al.
Publicado: (2015)

The impact of panitumumab treatment on survival and quality of life in patients with RAS wild-type metastatic colorectal cancer
por: Battaglin, Francesca, et al.
Publicado: (2019)

Cost-effectiveness of cetuximab and panitumumab for chemotherapy-refractory metastatic colorectal cancer
por: Carvalho, Adriana Camargo, et al.
Publicado: (2017)

Treatment of Recurrent Metastatic Head and Neck Cancer: Focus on Cetuximab
por: Patel, Akshar N., et al.
Publicado: (2012)

Clinical Pharmacokinetics and Pharmacodynamics of the Epidermal Growth Factor Receptor Inhibitor Panitumumab in the Treatment of Colorectal Cancer
por: Ketzer, Sander, et al.
Publicado: (2017)

Tailored Treatment of Colorectal Cancer: Surgical, Molecular, and Genetic Considerations
por: Augestad, Knut Magne, et al.
Publicado: (2017)

The Role of Pre-treatment Inflammatory Biomarkers in the Prediction of an Early Response to Panitumumab in Metastatic Colorectal Cancer
por: Lasagna, Angioletta, et al.
Publicado: (2022)

Panitumumab-Induced Eruptive Seborrhoeic Keratosis in a Patient with Metastatic Colorectal Cancer
por: Koumaki, Dimitra, et al.
Publicado: (2020)

A Comprehensive Review of Clinical Trials on EGFR Inhibitors Such as Cetuximab and Panitumumab as Monotherapy and in Combination for Treatment of Metastatic Colorectal Cancer
por: Yazdi, Mohammad Hossein, et al.
Publicado: (2015)

Novel Treatments for Metastatic Cutaneous Melanoma and the Management of Emergent Toxicities
por: Lemech, Charlotte, et al.
Publicado: (2012)

FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer
por: Geredeli, Caglayan, et al.
Publicado: (2018)

Health-related quality of life in patients with metastatic colorectal cancer treated with panitumumab in first- or second-line treatment
por: Bennett, L, et al.
Publicado: (2011)

The efficacy and safety of panitumumab plus irrinotecan-based chemotherapy in the treatment of metastatic colorectal cancer: A meta-analysis
por: Chen, Qiang, et al.
Publicado: (2016)

Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature
por: Zaccara, Gaetano, et al.
Publicado: (2009)

Trastuzumab for HER2-Positive Metastatic Breast Cancer: Clinical and Economic Considerations
por: Jeyakumar, Alwin, et al.
Publicado: (2012)

Critical appraisal of the long-term impact of memantine in treatment of moderate to severe Alzheimer’s disease
por: Puangthong, Umamon, et al.
Publicado: (2009)

Influenza in long‐term care facilities
por: Lansbury, Louise E., et al.
Publicado: (2017)

Ipilimumab Pharmacotherapy in Patients with Metastatic Melanoma
por: Jeter, Joanne M., et al.
Publicado: (2012)

Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab
por: Kim, George P, et al.
Publicado: (2008)

Vemurafenib and panitumumab combination tailored therapy in BRAF-mutated metastatic colorectal cancer: A case report
por: Capalbo, Carlo, et al.
Publicado: (2014)

Chemotherapy plus Panitumumab Versus Chemotherapy plus Bevacizumab in Metastatic Colorectal Cancer: A Meta-analysis
por: Li, Zhigui, et al.
Publicado: (2018)

The impact of hepatic and renal function on panitumumab exposures in patients with metastatic RAS wild-type colorectal cancer
por: Liao, Michael Z., et al.
Publicado: (2021)

Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2022)

Long-Lasting Tumor Response in Patients with Panitumumab Monotherapy for Chemorefractory Metastatic Colorectal Carcinoma – A Report of Two Cases
por: Ramadori, G., et al.
Publicado: (2010)

Risperidone long-acting injection: a review of its long term safety and efficacy
por: Rainer, Michael K
Publicado: (2008)

Biologic Response of Colorectal Cancer Xenograft Tumors to Sequential Treatment with Panitumumab and Bevacizumab
por: Taniguchi, Hiroya, et al.
Publicado: (2018)

A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients
por: Elez, Elena, et al.
Publicado: (2019)

Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumab
por: Hoda, Daanish, et al.
Publicado: (2008)

Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumab
por: Williams, Kerry J, et al.
Publicado: (2009)

Effectiveness and safety of capecitabine, irinotecan and panitumumab in advanced colorectal cancer
por: Yip, Pui Lam, et al.
Publicado: (2023)

The efficacy and safety of panitumumab in the treatment of patients with metastatic colorectal cancer: a meta-analysis from five randomized controlled trials
por: Liang, Ruo-feng, et al.
Publicado: (2015)

Panitumumab Induced Forearm Panniculitis in Two Women With Metastatic Colon Cancer
por: Domenico, Ciliberto, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_bi5ha8m42mlumdsk0lh0ntdo6a